pembrolizumab
merck
['lcsm,(-blcsm)', 'nsclc', 'sclc', 'keynote-189', 'pembro']
keynote-189: 5-y update: the study that changed the standard treatment of metastatic nsqnsclc.5-y os: 19.4% vs 11.3%,5-y pfs: 7.5% vs 0.6%. 72% of pts who completed 35 cycles of pembrolizumab were alive 3 y after completion of 35 cycles #lcsm 
Associate Head Oncology. Fundación Jiménez Díaz. IIS - FJD. Head of Thoracic Oncology & Clinical Trials. Professor of Oncology Universidad Autónoma Madrid Spain